Brown, Landon C. http://orcid.org/0000-0002-5231-4859
Desai, Kunal http://orcid.org/0000-0002-7653-0441
Zhang, Tian http://orcid.org/0000-0001-8914-3531
Ornstein, Moshe C.
Article History
First Online: 13 October 2020
Declarations
:
: No external funding was used in the preparation of this manuscript.
: Dr Landon Brown and Dr Kunal Desai declare that they have no conflicts of interest that might be relevant to the contents of this manuscript. Dr Tian Zhang declares that she has research funding from Astra Zeneca, Janssen, OmniSeq, PGDx, Pfizer, Merrimack, Abbvie/Stemcentrx, Novartis, Merck, Mirati, Astellas, and Regeneron; Advisory/consultant role with Genentech Roche, Exelixis, Bayer, AstraZeneca, Pfizer, Sanofi-Aventis, Janssen, Foundation Medicine, Amgen, BMS, Merck, Pharmacyclics, and Seattle Genetics; Speakers’ bureau for Genentech Roche (2018), Exelixis (2019), Sanofi-Aventis, Genomic Health/Exact Sciences; and Stocks/Employment from Capio Biosciences and Archimmune Therapeutics (spouse). Dr Moshe Ornstein declares research funding from Pfizer & Bristol-Myers Squibb; advisory/consulting roles from Pfizer, Bristol-Myers Squibb, Exelixis; Speakers’ bureau for Bristol Myers Squibb (2019) and Exelixis (2019).
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Drs Landon Brown and Kunal Desai wrote the majority of the content. Drs Tian Zhang and Moshe Ornstein reviewed all content and provided editorial input.